Format

Send to

Choose Destination
Endocr Relat Cancer. 2018 Jun;25(6):R351-R364. doi: 10.1530/ERC-18-0010. Epub 2018 Apr 11.

Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.

Author information

1
Department of Clinical Sciences and Community Health (DISCCO)University of Milan, Milan, Italy giovanni.vitale@unimi.it.
2
Laboratory of Geriatric and Oncologic Neuroendocrinology ResearchIstituto Auxologico Italiano IRCCS, Milan, Italy.
3
Department of Clinical Medicine and SurgeryUniversity of Naples Federico II, Naples, Italy.
4
Department of Emergency and Organ TransplantationSection of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
5
Unit of Gastrointestinal Medical Oncology and Neuroendocrine TumorsEuropean Institute of Oncology, IEO, Milan, Italy.

Abstract

Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

KEYWORDS:

neuroendocrine tumors; pasireotide; somatostatin analogs; somatostatin receptors

PMID:
29643113
DOI:
10.1530/ERC-18-0010

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center